Patent ID: 6692745
Filing Date: 2004-02-17
Classification: A61K,C07K

Abstract:
A composition which comprises an admixture of two compounds, wherein: (a) one compound is a CD4-IgG2 fusion protein comprising two heavy chains and two light chains, which heavy chains are encoded by an expression vector designated CD4-IgG2HC-pRcCMV (ATCC Accession No. 75193), and which light chains are encoded by an expression vector designated CD4-kLC-pRcCMV (ATCC Accession No. 75194), which compound retards attachment of HTV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and (b) the other compound is a peptide which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherein the peptide that retards gp41 comprises a portion of the gp41 extracellular domain, and wherein the relative mass ratio of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell.